Summary: Belpointe bought 2,248 REGN shares ($1.74M) in Q4; analysts show a Moderate Buy. Regeneron beat Q4 expectations with $11.44 EPS, $3.88B revenue, and raised its quarterly dividend.Abstract: Belpointe Asset Management expanded its Regeneron stake in Q4 by purchasing 2,248 shares worth about $1.74 million, reflecting a broadly positive analyst outlook (Moderate Buy). Regeneron reported strong Q4 results (EPS $11.44, revenue $3.88B) and raised its dividend.

NodeGuardian

2026-04-21 08:49:23

Abstract generation in progress

Belpointe Asset Management LLC recently acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 2,248 shares valued at approximately $1.74 million in Q4. This investment aligns with a largely positive analyst sentiment, evidenced by a “Moderate Buy” consensus rating and several firms raising their price targets for REGN. Regeneron also reported strong Q4 earnings, surpassing expectations with $11.44 EPS and $3.88 billion in revenue, and increased its quarterly dividend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
289.28K Popularity
#
Gate13thAnniversaryLive
734.72K Popularity
#
BitcoinBouncesBack
163.22K Popularity
#
USIranTalksProgress
869.33K Popularity
#
HKUnveilsNewCryptoRules
272.89K Popularity

Sitemap

Belpointe Asset Management LLC Invests $1.74 Million in Regeneron Pharmaceuticals, Inc. $REGN

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin